You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours

  • Technology appraisal guidance
  • Reference number: TA86
  • Published:  27 October 2004
  • Last updated:  01 November 2010
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence and interpretation
  • 5 Recommendations for further research
  • 6 Implications for the NHS
  • 7 Implementation and audit
  • 8 Appraisal Committee members and NICE project team
  • 9 Sources of evidence considered by the Committee
  • Appendix A Detail on criteria for audit of the use of imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
  • Appendix B Southwest Oncology Group (SWOG) criteria for assessing tumour response
  • Update information

Update information

November 2010: Recommendation 1.5 was updated and replaced by NICE technology appraisal guidance on imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (NICE technology appraisal guidance 209).

ISBN: 978-1-4731-7002-5


Previous page Appendix B Southwest Oncology Group (SWOG) criteria for assessing tumour response
Back to top